Fuller & Thaler Asset Management Inc. Has $25.60 Million Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Fuller & Thaler Asset Management Inc. reduced its stake in Medpace Holdings, Inc. by 17.4%, holding approximately $25.60 million worth of the company's stock as of the latest SEC filing.
• Medpace reported quarterly earnings that exceeded expectations, with earnings per share of $3.10, beating the consensus estimate of $3.00, and quarterly revenue of $603.31 million, up 14.2% from the previous year.
• Several analysts have recently adjusted their price targets for Medpace, with estimates ranging from $366 to $510, reflecting mixed outlooks with some ratings declining to sell.

Fuller & Thaler Asset Management Inc. lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 17.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,002 shares of the company's stock after selling 17,729 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 0.29% of Medpace worth $25,595,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Barclays PLC increased its position in Medpace by 42.4% in the 4th quarter. Barclays PLC now owns 28,166 shares of the company's stock valued at $9,359,000 after acquiring an additional 8,385 shares in the last quarter. Mariner LLC grew its position in shares of Medpace by 42.3% during the 4th quarter. Mariner LLC now owns 2,825 shares of the company's stock worth $939,000 after buying an additional 840 shares during the period. Marshall Wace LLP acquired a new stake in shares of Medpace during the 4th quarter worth approximately $4,795,000. Commerce Bank grew its position in shares of Medpace by 15.9% during the 4th quarter. Commerce Bank now owns 2,058 shares of the company's stock worth $684,000 after buying an additional 283 shares during the period. Finally, GeoWealth Management LLC grew its position in shares of Medpace by 27.8% during the 4th quarter. GeoWealth Management LLC now owns 285 shares of the company's stock worth $95,000 after buying an additional 62 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Down 0.2%

Medpace stock opened at $462.14 on Wednesday. The stock has a market capitalization of $12.98 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.91 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The company has a 50 day moving average of $369.30 and a 200-day moving average of $332.71.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on MEDP shares. Robert W. Baird lifted their price target on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. TD Cowen reiterated a "sell" rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Mizuho lifted their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Barclays lifted their price target on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Medpace currently has an average rating of "Reduce" and a consensus target price of $406.60.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 7,500 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the transaction, the vice president owned 57,500 shares in the company, valued at $25,883,050. This represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the sale, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 112,788 shares of company stock valued at $51,018,354. 20.30% of the stock is owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.